Antioxidant Capacity Is Decreased in Wilson's Disease and Correlates to Liver Function.
Antioxidant capacity
Copper
Oxidative stress
Wilson’s disease
Journal
Biological trace element research
ISSN: 1559-0720
Titre abrégé: Biol Trace Elem Res
Pays: United States
ID NLM: 7911509
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
22
03
2022
accepted:
01
05
2022
pubmed:
8
5
2022
medline:
18
2
2023
entrez:
7
5
2022
Statut:
ppublish
Résumé
The metabolic disorder Wilson's disease (WD) is caused by copper accumulation in the tissues due to a biallelic pathogenic mutation of the gene ATP7B, encoding intracellular copper transporter ATPase-7B. As copper is a redox active metal; aberrations in its homeostasis may create favourable conditions for superoxide-yielding redox cycling and oxidative damage to the cells. We tried to characterise antioxidant defence in WD patients and to evaluate whether it is related to liver function. The blood glutathione concentration, the activity of manganese-SOD (MnSOD), catalase (Cat), glutathione peroxidase, and glutathione S-transferase glutathione (GST), and serum antioxidant potential (AOP-450) were measured in WD treatment-naive patients and healthy controls and correlated with clinical data. The blood glutathione concentration, the activity of MnSOD, Cat, glutathione peroxidase, and GST and AOP-450 are significantly decreased in WD patients. There was a positive correlation of AOP-450 with AST. Moreover, the Cat and GST activity as well as AOP-450 strongly correlated with parameters of synthetic liver function. MnSOD activity correlated positively with ALT and AST.The blood glutathione concentration, the activity of MnSOD, Cat, glutathione peroxidase, and GST and AOP-450 are significantly decreased in WD patients. There was a positive correlation of AOP-450 with AST. Moreover, the Cat and GST activity as well as AOP-450 strongly correlated with parameters of synthetic liver function. MnSOD activity correlated positively with ALT and AST. Liver injury in course of WD is linked with decreased antioxidant capacity.
Identifiants
pubmed: 35524917
doi: 10.1007/s12011-022-03277-5
pii: 10.1007/s12011-022-03277-5
doi:
Substances chimiques
Antioxidants
0
Copper
789U1901C5
Glutathione
GAN16C9B8O
Glutathione Peroxidase
EC 1.11.1.9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1582-1587Subventions
Organisme : Narodowe Centrum Badań i Rozwoju
ID : N N402 375239
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Ala A et al (2007) Wilson’s disease. Lancet 369(9559):397–408
doi: 10.1016/S0140-6736(07)60196-2
pubmed: 17276780
Bitter RM et al. (2022) Structure of the Wilson disease copper transporter ATP7B. Sci Adv 8(9): p. eabl5508.
Wallace DF, Dooley JS (2020) ATP7B variant penetrance explains differences between genetic and clinical prevalence estimates for Wilson disease. Hum Genet 139(8):1065–1075
doi: 10.1007/s00439-020-02161-3
pubmed: 32248359
Boga S, Ala A, Schilsky ML (2017) Hepatic features of Wilson disease. Handb Clin Neurol 142:91–99
doi: 10.1016/B978-0-444-63625-6.00009-4
pubmed: 28433114
Ferenci P et al (2007) Late-onset Wilson’s disease. Gastroenterology 132(4):1294–8
doi: 10.1053/j.gastro.2007.02.057
pubmed: 17433323
Ferenci P et al (2019) Age and sex but not ATP7B genotype effectively influence the clinical phenotype of wilson disease. Hepatology 69(4):1464–1476
doi: 10.1002/hep.30280
pubmed: 30232804
Chen J et al (2020) The molecular mechanisms of copper metabolism and its roles in human diseases. Pflugers Arch 472(10):1415–1429
doi: 10.1007/s00424-020-02412-2
pubmed: 32506322
Ercal N, Gurer-Orhan H, Aykin-Burns N (2001) Toxic metals and oxidative stress part I: mechanisms involved in metal-induced oxidative damage. Curr Top Med Chem 1(6):529–39
doi: 10.2174/1568026013394831
pubmed: 11895129
Jomova K, Valko M (2011) Advances in metal-induced oxidative stress and human disease. Toxicology 283(2–3):65–87
doi: 10.1016/j.tox.2011.03.001
pubmed: 21414382
Flora SJ, Shrivastava R, Mittal M (2013) Chemistry and pharmacological properties of some natural and synthetic antioxidants for heavy metal toxicity. Curr Med Chem 20(36):4540–74
doi: 10.2174/09298673113209990146
pubmed: 24206124
Pisoschi AM, Pop A (2015) The role of antioxidants in the chemistry of oxidative stress: a review. Eur J Med Chem 97:55–74
doi: 10.1016/j.ejmech.2015.04.040
pubmed: 25942353
Ali SS et al (2020) Understanding oxidants and antioxidants: classical team with new players. J Food Biochem 44(3):e13145
doi: 10.1111/jfbc.13145
pubmed: 31960481
Gaetke LM, Chow CK (2003) Copper toxicity, oxidative stress, and antioxidant nutrients. Toxicology 189(1–2):147–63
doi: 10.1016/S0300-483X(03)00159-8
pubmed: 12821289
Yucel EM et al (2021) Investigation of dynamic thiol/disulfide homeostasis and nitrosative stress in patients with Wilson disease. Turk J Gastroenterol 32(9):765–773
doi: 10.5152/tjg.2021.20549
pubmed: 34609306
Ogihara H et al (1995) Plasma copper and antioxidant status in Wilson’s disease. Pediatr Res 37(2):219–26
doi: 10.1203/00006450-199502000-00016
pubmed: 7731761
Nagasaka H et al (2006) Relationship between oxidative stress and antioxidant systems in the liver of patients with Wilson disease: hepatic manifestation in Wilson disease as a consequence of augmented oxidative stress. Pediatr Res 60(4):472–7
doi: 10.1203/01.pdr.0000238341.12229.d3
pubmed: 16940238
Nagasaka H et al (2012) Fatty liver and anti-oxidant enzyme activities along with peroxisome proliferator-activated receptors gamma and alpha expressions in the liver of Wilson’s disease. Mol Genet Metab 107(3):542–7
doi: 10.1016/j.ymgme.2012.08.004
pubmed: 22940187
Nagasaka H, Takayanagi M, Tsukahara H (2009) Children’s toxicology from bench to bed--liver injury (3): oxidative stress and anti-oxidant systems in liver of patients with Wilson disease. J Toxicol Sci 34(Suppl 2): p. SP229-36
Bruha R et al (2012) Decreased serum antioxidant capacity in patients with Wilson disease is associated with neurological symptoms. J Inherit Metab Dis 35(3):541–8
doi: 10.1007/s10545-011-9422-5
pubmed: 22139496
Ferenci P et al (2003) Diagnosis and phenotypic classification of Wilson disease. Liver Int 23(3):139–42
doi: 10.1034/j.1600-0676.2003.00824.x
pubmed: 12955875
Kitzberger R, Madl C, Ferenci P (2005) Wilson disease. Metab Brain Dis 20(4):295–302
doi: 10.1007/s11011-005-7910-8
pubmed: 16382340
Gromadzka G et al (2005) Frameshift and nonsense mutations in the gene for ATPase7B are associated with severe impairment of copper metabolism and with an early clinical manifestation of Wilson’s disease. Clin Genet 68(6):524–32
doi: 10.1111/j.1399-0004.2005.00528.x
pubmed: 16283883
Gromadzka G et al (2010) Middle-aged heterozygous carriers of Wilson’s disease do not present with significant phenotypic deviations related to copper metabolism. J Genet 89(4):463–7
doi: 10.1007/s12041-010-0065-3
pubmed: 21273697
Ravin HA (1961) An improved colorimetric enzymatic assay of ceruloplasmin. J Lab Clin Med 58:161–8
pubmed: 13739892
Rossi L et al (2006) Copper imbalance and oxidative stress in neurodegeneration. Ital J Biochem 55(3–4):212–21
pubmed: 17274527
Yamamoto H et al (2001) In vivo evidence for accelerated generation of hydroxyl radicals in liver of Long-Evans Cinnamon (LEC) rats with acute hepatitis. Free Radic Biol Med 30(5):547–54
doi: 10.1016/S0891-5849(00)00496-2
pubmed: 11182525
Jimenez I et al (2002) Chronic exposure of HepG2 cells to excess copper results in depletion of glutathione and induction of metallothionein. Toxicol In Vitro 16(2):167–75
doi: 10.1016/S0887-2333(01)00117-5
pubmed: 11869879
Mukhopadhyay CK, Attieh ZK, Fox PL (1998) Role of ceruloplasmin in cellular iron uptake. Science 279(5351):714–7
doi: 10.1126/science.279.5351.714
pubmed: 9445478
Yamakura F et al (2007) In vitro preparation of iron-substituted human manganese superoxide dismutase: possible toxic properties for mitochondria. Free Radic Biol Med 43(3):423–30
doi: 10.1016/j.freeradbiomed.2007.04.024
pubmed: 17602958
Li S et al (2015) The role of oxidative stress and antioxidants in liver diseases. Int J Mol Sci 16(11):26087–124
doi: 10.3390/ijms161125942
pubmed: 26540040
pmcid: 4661801
Dalgic B et al (2005) Evaluation of oxidant stress in Wilson’s disease and non-Wilsonian chronic liver disease in childhood. Turk J Gastroenterol 16(1):7–11
pubmed: 16252181
Kalita J et al (2020) Adjunctive antioxidant therapy in neurologic Wilson’s disease improves the outcomes. J Mol Neurosci 70(3):378–385
doi: 10.1007/s12031-019-01423-8
pubmed: 31773400